Meeting
2022 ASCO Annual Meeting
Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab).
Authors
Andreas Jay Kind
Department of Hematology, Oncology and Cancer Immunology (CCM), Charité-Universtätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany
Andreas Jay Kind , Dominik Paul Modest , Christine Sers , Soulafa Mamlouk , Meinolf Karthaus , Stefan Fruehauf , Ullrich Graeven , Ludwig Fischer Von Weikersthal , Eray Goekkurt , Anke C. Reinacher-Schick , Stefan Kasper , Annika Kurreck , Beeke Hoppe , Swantje Held , Volker Heinemann , David Horst , Armin Jarosch , Sebastian Stintzing , Tanja Trarbach , Arndt Stahler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3536)
DOI
10.1200/JCO.2022.40.16_suppl.3536
Abstract #
3536
Poster Bd #
330
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.
First Author: Gemma Bruera
Poster
2011 ASCO Annual Meeting
Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
First Author: K. Oliner
Poster
2020 Gastrointestinal Cancers Symposium
Molecular profiling of early-stage colorectal cancer (CRC) using targeted next generation sequencing (NGS) to predict signatures of recurrence.
First Author: Michael C. Burns
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock